This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Cabergoline, an ergoline derivative, is a potent and highly specific D2 receptor agonist with a long duration of action. Controlled studies have demonstrated its effectiveness and favorable adverse effect profile in the treatment of Parkinson’s disease (PD).1 Dopamine agonists, such as apomorphine and ropinirole, increase penile erections and libido in patients with PD.2,3⇓ Recently, cabergoline induced improvement of gonadal function in hyperprolactinemic males was described,4 but cabergoline effects on penile erections and libido have not been noted.
Case report.
A 77-year-old man with a 5-year history of akinetic–rigid idiopathic PD (“on” state Unified PD Rating Scale [UPDRS]/motor subscale score, 19.5) received levodopa/benserazide up to 400 mg/day …
AAN Members: Sign in with your AAN member credentials (e-mail or 6-digit Member ID number)
Non-AAN Member subscribers: Sign in with subscriber credentials
Log in using your username and password
Purchase access
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.